Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01439152 (Clinical Trial/ BAY94-9343)

Study Title
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors (NCT01439152)

Trial Description
BAY94-9343 is an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells. This study will attempt to answer the following questions:
-What are the side effects of BAY94-9343 when given at different dose levels and schedules?
-What dose level and schedule of BAY94-9343 should be tested in future clinical research studies?
-How much BAY94-9343 is in the blood at specific times after  administration?
-Does the treatment with BAY94-9343 show any effect on the tumor growth?
-Are there specific biomarkers that might be able to explain why some patients respond to treatment and others do not?

This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Solid Tumors
  • Interventions:
    • Drugs used in this trial
      • BAY94-9343
  • Phase: I
  • Estimated Enrollment: 141
  • Start: September 2011
  • Estimated Completion: December 2015
  • Last verified: June 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar